Pharma News, 2024

Teva UK and Closed Loop Medicines have announced a strategic partnership that aims to advance the development of personalised medicines.

Researchers from the Science and Technologies Facilities Council’s (STFC) Central Laser Facility’s (CLF) Octopus Group have shown that a crucial interface in a lung cancer protein ...

Johnson & Johnson (J&J) is allegedly looking to strengthen its presence in the cardiovascular device market with the acquisition of medical device company Shockwave Medical, as first reported ...

The FDA has granted fast track designation to nipocalimab (Johnson & Johnson) to reduce the risk of fetal neonatal alloimmune thrombocytopenia (FNAIT) in pregnant adults who are alloim...

Irlab Therapeutics is preparing to start a Phase 3 clinical trial of mesdopetam, its experimental oral treatment intending to ease levodopa-induced dyskinesia, the uncontrolled movements affecting peo...

The FDA approved Ultomiris for the treatment of adults with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder, according to a press release from Alexion.

Gilead Sciences has concluded the acquisition of CymaBay Therapeutics for $4.3bn.

Sanofi and Owkin have announced the expansion of their collaboration in leveraging artificial intelligence (AI) to include drug positioning in immunology.

Lisata Therapeutics announced a Rare Pediatric Drug Designation for LSTA1, which is being studied in several early to mid-stage clinical studies.

Mission Therapeutics, a clinical-stage biotech developing first-in-class therapeutics targeting mitophagy, today announces the start of a Phase I first-in-human clinical trial of MTX325, its potential...

The US Food and Drug Administration (FDA) has approved Italfarmaco’s Duvyzat (givinostat) as the first nonsteroidal drug to treat patients with all genetic variants of Duchenne muscular dystroph...

BOSTON – Brain scans of a 72-year-old man diagnosed with a highly aggressive form of cancer known as a glioblastoma have revealed a remarkable regression in his tumor’s size within days of receivi...